Eli Lilly and Company (NYSE:LLY) Stock Holdings Cut by 1900 Wealth Management LLC

1900 Wealth Management LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 11.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 914 shares of the company’s stock after selling 114 shares during the quarter. 1900 Wealth Management LLC’s holdings in Eli Lilly and Company were worth $533,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of LLY. International Assets Investment Management LLC boosted its holdings in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the period. Sapient Capital LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth $617,312,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Eli Lilly and Company in the third quarter worth about $435,736,000. Vanguard Group Inc. raised its position in Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after acquiring an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Eli Lilly and Company by 24.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after acquiring an additional 645,473 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.4 %

Eli Lilly and Company stock traded up $10.28 during mid-day trading on Tuesday, hitting $741.61. The company’s stock had a trading volume of 561,260 shares, compared to its average volume of 3,031,223. Eli Lilly and Company has a 1 year low of $370.68 and a 1 year high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $704.65 billion, a PE ratio of 127.57, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The stock’s fifty day moving average is $763.83 and its two-hundred day moving average is $662.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter last year, the business earned $2.09 earnings per share. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LLY. Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Truist Financial reissued a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Morgan Stanley lifted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.